NPC
MCID: NSP012
MIFTS: 66

Nasopharyngeal Carcinoma (NPC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Nasopharyngeal Carcinoma

MalaCards integrated aliases for Nasopharyngeal Carcinoma:

Name: Nasopharyngeal Carcinoma 58 12 77 54 60 30 56 6 15 41 74
Nasopharyngeal Cancer 58 54 38
Malignant Neoplasm of Nasopharynx 12 74
Nasopharyngeal Carcinoma 1 58 13
Nasopharyngeal Neoplasms 45 74
Nasopharynx Carcinoma 12 15
Npc 58 17
Malignant Neoplasm of Other Specified Sites of Nasopharynx 12
Primary Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Posterior Wall of Nasopharynx 12
Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Superior Wall of Nasopharynx 12
Malignant Neoplasm of Lateral Wall of Nasopharynx 12
Malignant Tumor of Posterior Wall of Nasopharynx 12
Malignant Tumor of Anterior Wall of Nasopharynx 12
Malignant Tumor of Lateral Wall of Nasopharynx 12
Squamous Cell Carcinoma of the Nasopharynx 60
Malignant Neoplasm of Nasopharyngeal Wall 12
Malignant Neoplasm of Roof of Nasopharynx 12
Malignant Nasopharyngeal Tumor 12
Carcinoma of Nasopharynx 12
Nasopharyngeal Neoplasm 17
Cancer of Nasopharynx 74
Nasopharynx Cancer 12
Npca 58

Characteristics:

Orphanet epidemiological data:

60
nasopharyngeal carcinoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

HPO:

33
nasopharyngeal carcinoma:
Inheritance polygenic inheritance


Classifications:

Orphanet: 60  
Rare respiratory diseases


External Ids:

Disease Ontology 12 DOID:9261
OMIM 58 607107
KEGG 38 H00054
MeSH 45 D009303
NCIt 51 C9321
MESH via Orphanet 46 C538339
ICD10 via Orphanet 35 C11.0 C11.1 C11.2 more
UMLS via Orphanet 75 C0153392 C0238301 C2931822
Orphanet 60 ORPHA150
MedGen 43 C2931822
SNOMED-CT via HPO 70 126680004

Summaries for Nasopharyngeal Carcinoma

OMIM : 58 Nasopharyngeal carcinoma (NPC, NPCA) is a multifactorial malignancy associated with both genetic and environmental factors. The cancer arises from the epithelium of the nasopharynx. The Epstein-Barr virus has been implicated (Tse et al., 2009). (607107)

MalaCards based summary : Nasopharyngeal Carcinoma, also known as nasopharyngeal cancer, is related to squamous cell carcinoma and leukemia, and has symptoms including headache, tinnitus and rhinorrhea. An important gene associated with Nasopharyngeal Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Viral carcinogenesis and Epstein-Barr virus infection. The drugs Cisplatin and Docetaxel have been mentioned in the context of this disorder. Affiliated tissues include lymph node, lung and liver, and related phenotype is neoplasia of the nasopharynx.

Disease Ontology : 12 A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or \

Wikipedia : 77 Nasopharynx cancer or nasopharyngeal carcinoma (NPC) is the most common cancer originating in the... more...

Related Diseases for Nasopharyngeal Carcinoma

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 2 Nasopharyngeal Carcinoma 3

Diseases related to Nasopharyngeal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 355)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.0 CDKN2B-AS1 FOXCUT H19 HOTAIR HRAS MALAT1
2 leukemia 30.9 CDKN2B-AS1 HOTAIR NEAT1 NRAS TP53
3 adenocarcinoma 30.7 H19 HRAS MALAT1 PIK3CA TP53
4 acute lymphocytic leukemia 30.5 CDKN2B-AS1 TP53 XIST
5 tongue squamous cell carcinoma 30.5 AFAP1-AS1 MALAT1 TP53
6 squamous cell carcinoma, head and neck 30.4 H19 HOTAIR HRAS MIR29C PIK3CA TP53
7 laryngeal squamous cell carcinoma 30.4 CDKN2B-AS1 H19 HOTAIR MALAT1 NEAT1 TP53
8 renal cell carcinoma, nonpapillary 30.3 H19 HOTAIR MALAT1 NPTN-IT1
9 osteogenic sarcoma 30.3 CDKN2B-AS1 H19 HOTAIR MALAT1 NEAT1 TP53
10 myeloma, multiple 30.3 H19 HOTAIR HRAS MALAT1 NRAS TP53
11 esophageal cancer 30.2 CDKN2B-AS1 FOXD2-AS1 H19 HOTAIR HRAS MALAT1
12 prostate cancer 30.1 CDKN2B-AS1 H19 HOTAIR HRAS MALAT1 MIR100
13 thyroid cancer 30.1 AFAP1-AS1 CDKN2B-AS1 H19 HOTAIR HRAS LINC00312
14 breast cancer 30.0 CDKN2B-AS1 FOXCUT H19 HOTAIR HRAS MALAT1
15 melanoma 30.0 CDKN2B-AS1 H19 HOTAIR MALAT1 MIR100 NRAS
16 lung cancer 29.7 AFAP1-AS1 CDKN2B-AS1 FOXD2-AS1 H19 HOTAIR HRAS
17 nasopharyngeal carcinoma 3 12.6
18 nasopharyngeal carcinoma 2 12.5
19 nasopharyngeal cancer, childhood 12.2
20 niemann-pick disease, type c1 12.0
21 lymphoepithelioma-like carcinoma 11.5
22 niemann-pick disease, type c2 11.1
23 serous cystadenocarcinoma 10.7 HRAS PIK3CA TP53
24 cystadenocarcinoma 10.7 HRAS PIK3CA TP53
25 ovary adenocarcinoma 10.7 HRAS PIK3CA TP53
26 adult hepatocellular carcinoma 10.7 PIK3CA TP53
27 skin squamous cell carcinoma 10.7 HRAS PIK3CA TP53
28 malignant ovarian surface epithelial-stromal neoplasm 10.7 HRAS PIK3CA TP53
29 ovary epithelial cancer 10.7 HRAS PIK3CA TP53
30 rare adenocarcinoma of the breast 10.7 PIK3CA TP53
31 respiratory system cancer 10.7 HRAS MALAT1 PIK3CA TP53
32 carcinosarcoma 10.7 HRAS PIK3CA TP53
33 malignant spiradenoma 10.6 PIK3CA TP53
34 apocrine adenoma 10.6 HRAS PIK3CA
35 uterine carcinosarcoma 10.6 HRAS PIK3CA TP53
36 prostate adenoid cystic carcinoma 10.6 HRAS PIK3CA
37 intestinal disease 10.6 HRAS PIK3CA TP53
38 small cell cancer of the lung 10.6 HOTAIR MALAT1 PIK3CA TP53
39 triple-receptor negative breast cancer 10.6 HOTAIR MALAT1
40 prostate disease 10.6 CDKN2B-AS1 H19 MALAT1 TP53
41 esophagus squamous cell carcinoma 10.6 AFAP1-AS1 HOTAIR
42 suppression of tumorigenicity 12 10.6 HRAS PIK3CA TP53
43 ovarian epithelial cancer 10.6 H19 HOTAIR MALAT1 PIK3CA
44 spitz nevus 10.6 HRAS TP53
45 kidney cancer 10.6 H19 HOTAIR MALAT1 MIR29C TP53
46 lung squamous cell carcinoma 10.6 HRAS NPTN-IT1 PIK3CA TP53
47 gastrointestinal system cancer 10.6 H19 HOTAIR HRAS MALAT1 PIK3CA TP53
48 meningeal melanomatosis 10.6 HRAS NRAS TP53
49 hematologic cancer 10.6 HRAS NFKBIA TP53 XIST
50 marek disease 10.6 H19 TP53

Comorbidity relations with Nasopharyngeal Carcinoma via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Nasopharyngeal Carcinoma:



Diseases related to Nasopharyngeal Carcinoma

Symptoms & Phenotypes for Nasopharyngeal Carcinoma

Human phenotypes related to Nasopharyngeal Carcinoma:

33
# Description HPO Frequency HPO Source Accession
1 neoplasia of the nasopharynx 33 HP:0100630

Clinical features from OMIM:

607107

UMLS symptoms related to Nasopharyngeal Carcinoma:


headache, tinnitus, rhinorrhea

Drugs & Therapeutics for Nasopharyngeal Carcinoma

Drugs for Nasopharyngeal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 364)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
2
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
3
Bupropion Approved Phase 4,Phase 2,Early Phase 1 34841-39-9, 34911-55-2 444
4
Dopamine Approved Phase 4,Phase 2,Early Phase 1 62-31-7, 51-61-6 681
5
Nicotine Approved Phase 4,Early Phase 1,Not Applicable 54-11-5 942 89594
6
Nimotuzumab Investigational Phase 4,Phase 3,Phase 2,Phase 1 780758-10-3, 828933-61-3
7 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
10 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
12 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3,Early Phase 1
13 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
15 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2,Early Phase 1
16 Dopamine Uptake Inhibitors Phase 4,Phase 2,Early Phase 1
17 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Early Phase 1
18 Dopamine Agents Phase 4,Phase 2,Early Phase 1
19 Antidepressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
20 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Early Phase 1
21 Cholinergic Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
22 Nicotinic Agonists Phase 4,Early Phase 1,Not Applicable
23 Central Nervous System Stimulants Phase 4,Phase 3,Early Phase 1,Not Applicable
24
Nedaplatin Approved, Investigational Phase 3,Phase 2,Phase 1 95734-82-0
25
Celecoxib Approved, Investigational Phase 3,Phase 2,Phase 1 169590-42-5 2662
26
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
27
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
28
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
29
Aprepitant Approved, Investigational Phase 3,Phase 2 170729-80-3 151165 6918365
30
Fosaprepitant Approved Phase 3,Phase 2 172673-20-0 219090
31
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
33
Palonosetron Approved, Investigational Phase 3,Phase 2 135729-61-2, 119904-90-4, 135729-56-5 148211
34
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
35
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
36
Racepinephrine Approved Phase 3,Phase 2 329-65-7 838
37
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
38
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
39
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
40
Cetuximab Approved Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
41
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
42
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
43
Levoleucovorin Approved, Investigational Phase 3,Phase 2 68538-85-2
44
Amifostine Approved, Investigational Phase 3,Phase 1,Phase 2 20537-88-6 2141
45
Sargramostim Approved, Investigational Phase 3,Phase 2,Not Applicable 123774-72-1, 83869-56-1
46
Acyclovir Approved Phase 3 59277-89-3 2022
47
Oprelvekin Approved, Investigational Phase 3 145941-26-0
48
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
49
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
50
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4

Interventional clinical trials:

(show top 50) (show all 603)
# Name Status NCT ID Phase Drugs
1 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Unknown status NCT02293356 Phase 4 Nimotuzumab Injection
2 Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury Unknown status NCT03069820 Phase 4 docetaxel and cisplatin
3 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Active, not recruiting NCT02948699 Phase 4
4 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
5 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
6 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
7 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
8 The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
9 The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT Unknown status NCT01817023 Phase 3 Cisplatin
10 A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
11 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
12 Induction Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT01245959 Phase 3 Docetaxel, cisplatin and fluorouracil
13 Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT02944708 Phase 3 Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2
14 Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
15 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
16 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
17 EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients Unknown status NCT03006588 Phase 2, Phase 3
18 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
19 Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma Unknown status NCT01528618 Phase 3 gemcitabine and cisplatin;5-Fluorouracil and cisplatin
20 Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
21 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
22 Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC). Unknown status NCT02012062 Phase 3 TPF neoadjuvant chemotherapy;Concurrent chemotherapy with cisplatin during radiotherapy;Concurrent nimotuzumab during radiotherapy
23 PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE. Unknown status NCT00180973 Phase 3 Hydroxyurea
24 Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx Unknown status NCT00003637 Phase 3 cisplatin;fluorouracil
25 A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02444949 Phase 3 endostar;cisplatin
26 Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Unknown status NCT02933099 Phase 3 Aprepitant+palonosetron+dexamethasone;palonosetron+dexamethasone
27 Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
28 A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer Unknown status NCT02395016 Phase 3 nimotuzumab;Gemcitabine
29 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
30 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
31 Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma Recruiting NCT03321539 Phase 3 CCRT+GP;CCRT+PF
32 TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma Recruiting NCT03306121 Phase 3 TPF+CCRT;CCRT+ PF
33 TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma Recruiting NCT02940925 Phase 3
34 IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma Not yet recruiting NCT03068936 Phase 3 Cisplatin
35 The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT Recruiting NCT02460887 Phase 3 Gemcitabine;cisplatin;cisplatin
36 Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma Not yet recruiting NCT02907710 Phase 3 Endostar;DDP
37 Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
38 Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Active, not recruiting NCT02958111 Phase 3 Capecitabine
39 Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma Recruiting NCT02460419 Phase 3 capecitabine
40 Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma Recruiting NCT03707509 Phase 3 Camrelizumab;Placebos;Gemcitabine;Cisplatin
41 Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma Recruiting NCT02111460 Phase 3
42 Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma Recruiting NCT03015727 Phase 3 Docetaxel;Cisplatin;Chemotherapy
43 Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma Not yet recruiting NCT02786641 Phase 3 Docetaxel;Cisplatin 1;Xeloda;Cisplatin 2
44 Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Active, not recruiting NCT01872962 Phase 3 gemcitabine and cisplatin (Induction chemotherapy)
45 A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients Recruiting NCT02578641 Phase 3 combination IV gemcitabine and IV carboplatin (AUC2)
46 Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage Recruiting NCT03403829 Phase 3 Gemcitabine
47 Gemcitabine and Cisplatin With/Without Anlotinib in Advanced Nasopharyngeal Carcinoma Recruiting NCT03601975 Phase 3 Gemcitabine/Cisplatin
48 A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma Recruiting NCT02512315 Phase 3 Docetaxel (DOC);Cisplatin (DDP)
49 Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial Active, not recruiting NCT02143388 Phase 2, Phase 3 IMRT combine with cisplatin concurrent chemotherapy;IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
50 Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma Not yet recruiting NCT03344068 Phase 2, Phase 3 Chemotherapy

Search NIH Clinical Center for Nasopharyngeal Carcinoma

Cochrane evidence based reviews: nasopharyngeal neoplasms

Genetic Tests for Nasopharyngeal Carcinoma

Genetic tests related to Nasopharyngeal Carcinoma:

# Genetic test Affiliating Genes
1 Nasopharyngeal Carcinoma 30 TP53

Anatomical Context for Nasopharyngeal Carcinoma

MalaCards organs/tissues related to Nasopharyngeal Carcinoma:

42
Lymph Node, Lung, Liver, Bone, Brain, T Cells, Skin

Publications for Nasopharyngeal Carcinoma

Articles related to Nasopharyngeal Carcinoma:

(show top 50) (show all 5219)
# Title Authors Year
1
A nomogram for the prediction of cerebrovascular disease among patients with brain necrosis after radiotherapy for nasopharyngeal carcinoma. ( 30825967 )
2019
2
EBV-Associated Non-keratinizing Nasopharyngeal Carcinoma with Prominent Spindled Cell and Whorling Patterns: A Previously Unreported Histological Variant in a Patient Presenting with Dermatomyositis. ( 30758756 )
2019
3
Office-Based Cricopharyngeus Balloon Dilation for Post Chemoirradiation Dysphagia in Nasopharyngeal Carcinoma Patients: A Pilot Study. ( 30888528 )
2019
4
Radiotherapy-induced dysphagia and its impact on quality of life in patients with nasopharyngeal carcinoma. ( 30689027 )
2019
5
miR-193a-3p Promotes Radio-Resistance of Nasopharyngeal Cancer Cells by Targeting SRSF2 Gene and Hypoxia Signaling Pathway. ( 30773530 )
2019
6
Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: a prospective clinical trial. ( 30712098 )
2019
7
Cancer-Specifically Re-Spliced TSG101 mRNA Promotes Invasion and Metastasis of Nasopharyngeal Carcinoma. ( 30759747 )
2019
8
Predictive factors of chemotherapy use in stage II nasopharyngeal carcinoma: A retrospective cohort study. ( 30762786 )
2019
9
EVI1 promotes epithelial-to-mesenchymal transition, cancer stem cell features and chemo-/radioresistance in nasopharyngeal carcinoma. ( 30770775 )
2019
10
Prognostic Value of the Pretreatment Primary Lesion Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Nasopharyngeal Carcinoma. ( 30772137 )
2019
11
NFAT1 Hypermethylation Promotes Epithelial-Mesenchymal Transition and Metastasis in Nasopharyngeal Carcinoma by Activating ITGA6 Transcription. ( 30772768 )
2019
12
The value of detailed MR imaging report of primary tumor and lymph nodes on prognostic nomograms for nasopharyngeal carcinoma after intensity-modulated radiotherapy. ( 30773185 )
2019
13
Down-regulation of miR-1181 indicates a dismal prognosis for nasopharyngeal carcinoma and promoted cell proliferation and metastasis by modulating Wnt/β-catenin signaling. ( 30779075 )
2019
14
A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma. ( 30782977 )
2019
15
Synthesis and Activity Evaluation of Nasopharyngeal Carcinoma Inhibitors Based on 6-(pyrimidin-4-yl)-1H-indazole. ( 30788913 )
2019
16
The role of chemotherapy in the treatment of stage II nasopharyngeal carcinoma: Retrospective analysis of the national cancer database. ( 30790468 )
2019
17
MicroRNA-506 inhibits tumor growth and metastasis in nasopharyngeal carcinoma through the inactivation of the Wnt/β-catenin signaling pathway by down-regulating LHX2. ( 30791932 )
2019
18
Body mass index, body shape, and risk of nasopharyngeal carcinoma: A population-based case-control study in Southern China. ( 30793524 )
2019
19
Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma. ( 30797141 )
2019
20
Epstein-Barr virus-encoded LMP1 regulated Pim1 kinase expression promotes nasopharyngeal carcinoma cells proliferation. ( 30809095 )
2019
21
An Unusual Presentation of Nasopharyngeal Carcinoma as Lemierre Syndrome. ( 30814483 )
2019
22
Metabolic characteristics revealing cell differentiation of nasopharyngeal carcinoma by combining NMR spectroscopy with Raman spectroscopy. ( 30820190 )
2019
23
Highly Uniform Synthesis of Selenium Nanoparticles with EGFR Targeting and Tumor Microenvironment Responsive Ability for Simultaneous Diagnosis and Therapy of Nasopharyngeal Carcinoma. ( 30821437 )
2019
24
Amyloid and hyaline globules in undifferentiated nasopharyngeal carcinoma. ( 30822626 )
2019
25
Dione-thiophene conjugate inhibits proliferation and metastasis of nasopharyngeal carcinoma cells through calcium binding protein-P down-regulation. ( 30822709 )
2019
26
TAT peptide-modified cisplatin-loaded iron oxide nanoparticles for reversing cisplatin-resistant nasopharyngeal carcinoma. ( 30826059 )
2019
27
Retinal crystalline deposits in a patient who received chemotherapy and radiotherapy for nasopharyngeal carcinoma and subsequent anti-VEGF treatment for the bilateral radiation maculopathy. ( 30828511 )
2019
28
The identification of key genes in nasopharyngeal carcinoma by bioinformatics analysis of high-throughput data. ( 30830589 )
2019
29
Nasopharyngeal Carcinoma Presenting as a Diffuse Face and Neck Swelling. ( 30832503 )
2019
30
Cost-effectiveness of Screening for Nasopharyngeal Carcinoma among Asian American Men in the United States. ( 30832545 )
2019
31
Ultrasound Elastography supplement assessing nodal status of magnetic resonance imaging staged cervical N0 patients with nasopharyngeal carcinoma. ( 30832735 )
2019
32
Expression of vimentin in nasopharyngeal carcinoma and its possible molecular mechanism: A study based on immunohistochemistry and bioinformatics analysis. ( 30833029 )
2019
33
miR-144-3p facilitates nasopharyngeal carcinoma via crosstalk with PTEN. ( 30834525 )
2019
34
Predictors of the therapeutic effect of corticosteroids on radiation-induced optic neuropathy following nasopharyngeal carcinoma. ( 30834973 )
2019
35
Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein-Barr Virus: An analysis of a prospective study in southern China. ( 30843658 )
2019
36
The antitumor effect of resveratrol on nasopharyngeal carcinoma cells. ( 30844723 )
2019
37
Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual. ( 30846172 )
2019
38
The prevalence and impact of cervical spine pathologies in patients with nasopharyngeal carcinoma. ( 30846176 )
2019
39
Effect of CRP and Kinetics of CRP in Prognosis of Nasopharyngeal Carcinoma. ( 30847301 )
2019
40
Long noncoding RNA DANCR promotes nasopharyngeal carcinoma progression by interacting with STAT3, enhancing IL-6/JAK1/STAT3 signaling. ( 30849642 )
2019
41
Epstein-Barr Virus MicroRNAs in Nasopharyngeal Carcinoma. ( 30852739 )
2019
42
Reprint of Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy. ( 30853080 )
2019
43
Corrigendum to "Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy" [Oral Oncol. 89 (2019) 40-47]. ( 30853081 )
2019
44
O Blood Type Is Associated with Unfavorable Distant-metastasis-free Survival in Female Patients with Nasopharyngeal Carcinoma: A Retrospective Study of 2439 Patients from Epidemic Area. ( 30854139 )
2019
45
The role of cross-sectional imaging in suspected nasopharyngeal carcinoma. ( 30855169 )
2019
46
Effects and mechanisms of innate immune molecules on inhibiting nasopharyngeal carcinoma. ( 30855360 )
2019
47
Clinical application of diffusion-weighted magnetic resonance imaging in radiotherapy for nasopharyngeal carcinoma. ( 30856148 )
2019
48
Characteristics of symptom distress in Chinese nasopharyngeal carcinoma patients and its relation to mood disturbance: A cross-sectional study. ( 30859638 )
2019
49
PNUTS mediates ionizing radiation-induced CNE-2 nasopharyngeal carcinoma cell migration, invasion, and epithelial-mesenchymal transition via the PI3K/AKT signaling pathway. ( 30863088 )
2019
50
Protocadherin 17 is a tumor suppressor and is frequently methylated in nasopharyngeal carcinoma. ( 30863170 )
2019

Variations for Nasopharyngeal Carcinoma

ClinVar genetic disease variations for Nasopharyngeal Carcinoma:

6 (show top 50) (show all 58)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
2 TP53 NM_001126115.1(TP53): c.443G> T (p.Arg148Ile) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
3 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
4 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
5 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
6 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
7 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
8 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
9 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
10 HRAS NM_176795.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
11 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
12 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
13 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
14 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
15 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
16 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
17 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
18 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
19 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
20 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
21 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
22 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
23 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
24 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
25 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 GRCh38 Chromosome 1, 114713909: 114713909
26 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Uncertain significance rs121913254 NCBI36 Chromosome 1, 115058053: 115058053
27 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
28 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
29 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
30 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
31 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Uncertain significance rs138729528 GRCh38 Chromosome 17, 7675089: 7675089
32 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Uncertain significance rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
33 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
34 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
35 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
36 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 GRCh38 Chromosome 1, 114713907: 114713907
37 FGFR2 NM_000141.4(FGFR2): c.1645A> C (p.Asn549His) single nucleotide variant Likely pathogenic rs1057519045 GRCh37 Chromosome 10, 123258036: 123258036
38 FGFR2 NM_000141.4(FGFR2): c.1645A> C (p.Asn549His) single nucleotide variant Likely pathogenic rs1057519045 GRCh38 Chromosome 10, 121498522: 121498522
39 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
40 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh38 Chromosome 1, 114713908: 114713908
41 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
42 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
43 FGFR2 NM_000141.4(FGFR2): c.1647T> A (p.Asn549Lys) single nucleotide variant Likely pathogenic rs121913476 GRCh37 Chromosome 10, 123258034: 123258034
44 FGFR2 NM_000141.4(FGFR2): c.1647T> A (p.Asn549Lys) single nucleotide variant Likely pathogenic rs121913476 GRCh38 Chromosome 10, 121498520: 121498520
45 FGFR2 NM_022970.3(FGFR2): c.1917T> A (p.Asn639Lys) single nucleotide variant Likely pathogenic rs1057519854 GRCh37 Chromosome 10, 123247577: 123247577
46 FGFR2 NM_022970.3(FGFR2): c.1917T> A (p.Asn639Lys) single nucleotide variant Likely pathogenic rs1057519854 GRCh38 Chromosome 10, 121488063: 121488063
47 FGFR2 NM_000141.4(FGFR2): c.1642A> C (p.Ile548Leu) single nucleotide variant Likely pathogenic rs1057519901 GRCh37 Chromosome 10, 123258039: 123258039
48 FGFR2 NM_000141.4(FGFR2): c.1642A> C (p.Ile548Leu) single nucleotide variant Likely pathogenic rs1057519901 GRCh38 Chromosome 10, 121498525: 121498525
49 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
50 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh38 Chromosome 17, 7675089: 7675089

Cosmic variations for Nasopharyngeal Carcinoma:

9 (show top 50) (show all 818)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM2255920 ZNF609 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1984G>A p.A662T 15:64674838-64674838 0
2 COSM6973489 ZFHX3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.9572G>A p.G3191D 16:72788704-72788704 0
3 COSM6948029 ZFHX3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.8780G>T p.S2927I 16:72793902-72793902 0
4 COSM4995216 ZC3H13 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.44C>G p.T15S 13:46045464-46045464 0
5 COSM4995307 ZBTB17 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.281C>T p.A94V 1:15947048-15947048 0
6 COSM6924419 YAP1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1178C>A p.A393D 11:102229765-102229765 0
7 COSM4995092 VPS33A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.221C>A p.A74D 12:122263647-122263647 0
8 COSM4996600 VNN2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.83C>A p.A28D 6:132757801-132757801 0
9 COSM4995249 VANGL1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.884T>C p.L295P 1:115682435-115682435 0
10 COSM4996245 USP34 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.5131C>T p.Q1711* 2:61281110-61281110 0
11 COSM4997193 USP19 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3636G>T p.L1212F 3:49110728-49110728 0
12 COSM4995369 USH2A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.89T>C p.L30S 1:216422248-216422248 0
13 COSM2978223 USH1G upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.520G>A p.D174N 17:74920316-74920316 0
14 COSM4995852 USE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.370G>T p.E124* 19:17216307-17216307 0
15 COSM4996719 TTBK1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1757G>A p.R586Q 6:43263121-43263121 0
16 COSM4997149 TSR2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.187G>C p.D63H 23:54443414-54443414 0
17 COSM1524842 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1783G>A p.D595N 19:31277461-31277461 0
18 COSM4995873 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1121C>T p.P374L 19:31278123-31278123 0
19 COSM6956334 TSC2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1753C>T p.R585C 16:2070492-2070492 0
20 COSM6908589 TSC1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.973C>T p.Q325* 9:132911509-132911509 0
21 COSM6973473 TSC1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2190G>T p.E730D 9:132903669-132903669 0
22 COSM4995721 TRAF4 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.955C>G p.R319G 17:28749119-28749119 0
23 COSM6973476 TRAF2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.4G>A p.A2T 9:136898744-136898744 0
24 COSM6807199 TRAF2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1177C>T p.R393C 9:136923890-136923890 0
25 COSM2123037 TPR upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3879G>A p.M1293I 1:186341261-186341261 0
26 COSM4996315 TP63 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1413C>G p.S471R 3:189886457-189886457 0
27 COSM10662 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 0
28 COSM43559 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.517G>T p.V173L 17:7675095-7675095 0
29 COSM33648 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.559+1G>C p.? 17:7675052-7675052 0
30 COSM10660 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.818G>A p.R273H 17:7673802-7673802 0
31 COSM10808 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.488A>G p.Y163C 17:7675124-7675124 0
32 COSM11376 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.737T>G p.M246R 17:7674226-7674226 0
33 COSM43708 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.422G>A p.C141Y 17:7675190-7675190 0
34 COSM45026 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.560-2A>T p.? 17:7674973-7674973 0
35 COSM44140 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.596G>T p.G199V 17:7674935-7674935 0
36 COSM43555 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.736A>G p.M246V 17:7674227-7674227 0
37 COSM10654 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.637C>T p.R213* 17:7674894-7674894 0
38 COSM10648 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.524G>A p.R175H 17:7675088-7675088 0
39 COSM10659 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.817C>T p.R273C 17:7673803-7673803 0
40 COSM11073 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1024C>T p.R342* 17:7670685-7670685 0
41 COSM10656 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 0
42 COSM10645 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.527G>T p.C176F 17:7675085-7675085 0
43 COSM45589 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.1037A>C p.E346A 17:7670672-7670672 0
44 COSM69404 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.994-1G>A p.? 17:7670716-7670716 0
45 COSM10943 TP53 upper aerodigestive tract,nasopharynx,carcinoma,squamous cell carcinoma c.841G>C p.D281H 17:7673779-7673779 0
46 COSM10724 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.839G>C p.R280T 17:7673781-7673781 0
47 COSM45243 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.374C>G p.T125R 17:7675995-7675995 0
48 COSM11181 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.764T>C p.I255T 17:7674199-7674199 0
49 COSM43906 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.843C>A p.D281E 17:7673777-7673777 0
50 COSM43919 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.856G>T p.E286* 17:7673764-7673764 0

Copy number variations for Nasopharyngeal Carcinoma from CNVD:

7 (show all 41)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72234 12 7764270 8036678 Duplication CLEC4C Nasopharyngeal cancer
2 72235 12 7764270 8036678 Duplication NANOG Nasopharyngeal cancer
3 72236 12 7764270 8036678 Duplication NANOGNB Nasopharyngeal cancer
4 72237 12 7764270 8036678 Duplication SLC2A14 Nasopharyngeal cancer
5 72238 12 7764270 8036678 Duplication SLC2A3 Nasopharyngeal cancer
6 126614 19 19848080 20497256 Deletion MIR1270-1 Nasopharyngeal cancer
7 126615 19 19848080 20497256 Deletion MIR1270-2 Nasopharyngeal cancer
8 126616 19 19848080 20497256 Deletion ZNF253 Nasopharyngeal cancer
9 126617 19 19848080 20497256 Deletion ZNF486 Nasopharyngeal cancer
10 126618 19 19848080 20497256 Deletion ZNF682 Nasopharyngeal cancer
11 126619 19 19848080 20497256 Deletion ZNF826P Nasopharyngeal cancer
12 126620 19 19848080 20497256 Deletion ZNF90 Nasopharyngeal cancer
13 126621 19 19848080 20497256 Deletion ZNF93 Nasopharyngeal cancer
14 132647 19 59423491 59445355 Deletion LILRA6 Nasopharyngeal cancer
15 171484 3 168801287 168851758 Amplification EVI1 Nasopharyngeal cancer
16 171493 3 168867391 169381563 Amplification MDS1 Nasopharyngeal cancer
17 177937 3 65166887 65190844 Deletion Nasopharyngeal cancer
18 197433 5 176843000 176857208 Deletion LMP1 Nasopharyngeal cancer
19 205127 6 121025447 121050579 Deletion Nasopharyngeal cancer
20 210827 6 31463047 31563588 Deletion HCG26 Nasopharyngeal cancer
21 210828 6 31463047 31563588 Deletion HCP5 Nasopharyngeal cancer
22 210829 6 31463047 31563588 Deletion MICA Nasopharyngeal cancer
23 210832 6 31463297 31559455 Deletion HCG26 Nasopharyngeal cancer
24 210836 6 31463297 31559455 Deletion HCP5 Nasopharyngeal cancer
25 210840 6 31463297 31559455 Deletion MICA Nasopharyngeal cancer
26 212636 6 4007991 32935606 Deletion LMP2 Nasopharyngeal cancer
27 220654 7 140736 180194 Duplication CCDC146 Nasopharyngeal cancer
28 220655 7 140736 180194 Duplication LOC100132832 Nasopharyngeal cancer
29 220656 7 140736 180194 Duplication LOC100133091 Nasopharyngeal cancer
30 220657 7 140736 180194 Duplication PMS2L11 Nasopharyngeal cancer
31 220658 7 140736 180194 Duplication POMZP3 Nasopharyngeal cancer
32 222456 7 152200000 154700000 Duplication Nasopharyngeal cancer
33 222457 7 152200000 154700000 Duplication Nasopharyngeal cancer
34 222532 7 153118877 153284978 Duplication Nasopharyngeal cancer
35 222533 7 153118877 153284978 Duplication Nasopharyngeal cancer
36 224029 7 2721151 3758564 Duplication CARD11 Nasopharyngeal cancer
37 224030 7 2721151 3758564 Duplication GNA12 Nasopharyngeal cancer
38 227304 7 66680598 66860844 Deletion AR Nasopharyngeal cancer
39 229234 7 892539 3753994 Duplication Nasopharyngeal cancer
40 236340 8 15447307 15475846 Deletion TUSC3 Nasopharyngeal cancer
41 256863 9 9780222 9786577 Deletion Nasopharyngeal cancer

Expression for Nasopharyngeal Carcinoma

Search GEO for disease gene expression data for Nasopharyngeal Carcinoma.

Pathways for Nasopharyngeal Carcinoma

Pathways related to Nasopharyngeal Carcinoma according to KEGG:

38
# Name Kegg Source Accession
1 Viral carcinogenesis hsa05203
2 Epstein-Barr virus infection hsa05169

Pathways related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

(show all 50)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 HRAS NFKBIA NRAS PIK3CA TP53
2 12.78 HRAS NFKBIA NRAS PIK3CA TP53
3
Show member pathways
12.74 HRAS NFKBIA NRAS PIK3CA TP53
4
Show member pathways
12.63 HRAS NFKBIA NRAS PIK3CA TP53
5
Show member pathways
12.6 HRAS NFKBIA NRAS PIK3CA TP53
6
Show member pathways
12.55 HRAS NRAS PIK3CA TP53
7
Show member pathways
12.46 HRAS NRAS PIK3CA TP53
8
Show member pathways
12.45 HRAS NFKBIA NRAS PIK3CA
9
Show member pathways
12.41 HRAS NFKBIA NRAS PIK3CA TP53
10
Show member pathways
12.4 HRAS NFKBIA NRAS PIK3CA
11
Show member pathways
12.38 HRAS NFKBIA NRAS PIK3CA
12
Show member pathways
12.37 HRAS NFKBIA NRAS PIK3CA
13
Show member pathways
12.33 HRAS NFKBIA PIK3CA TP53
14
Show member pathways
12.3 HRAS NFKBIA NRAS PIK3CA
15
Show member pathways
12.24 HRAS NFKBIA PIK3CA TP53
16
Show member pathways
12.24 HRAS NFKBIA NRAS PIK3CA
17 12.19 HRAS NRAS PIK3CA TP53
18
Show member pathways
12.17 HRAS NFKBIA NRAS TP53
19
Show member pathways
12.15 HRAS NRAS PIK3CA TP53
20
Show member pathways
12.14 HRAS NFKBIA NRAS PIK3CA TP53
21
Show member pathways
12.1 HRAS NFKBIA NRAS PIK3CA
22
Show member pathways
12.07 HRAS NFKBIA NRAS PIK3CA
23 12.04 HRAS NRAS PIK3CA TP53
24
Show member pathways
12.03 HRAS NRAS PIK3CA TP53
25 12.02 HRAS NRAS PIK3CA TP53
26 12 HRAS NFKBIA NRAS PIK3CA TP53
27
Show member pathways
11.99 HRAS NFKBIA NRAS PIK3CA
28
Show member pathways
11.97 HRAS NRAS PIK3CA TP53
29 11.93 HRAS NRAS TP53
30
Show member pathways
11.91 HRAS NRAS PIK3CA
31 11.87 HRAS NRAS PIK3CA
32 11.86 HRAS NFKBIA NRAS PIK3CA TP53
33 11.83 HRAS NRAS PIK3CA TP53
34 11.82 NFKBIA PIK3CA TP53
35
Show member pathways
11.8 HRAS NRAS PIK3CA
36 11.8 HRAS NRAS PIK3CA TP53
37 11.77 HRAS NRAS PIK3CA TP53
38
Show member pathways
11.73 HRAS NRAS PIK3CA
39 11.66 HRAS NRAS TP53
40 11.61 HRAS PIK3CA TP53
41 11.59 HRAS NRAS TP53
42 11.58 HRAS MIR100 MIR29C NRAS PIK3CA TP53
43 11.27 HRAS NRAS TP53
44
Show member pathways
11.15 HRAS NFKBIA PIK3CA
45 11.07 HRAS NRAS PIK3CA TP53
46 11.02 HRAS NRAS PIK3CA
47 10.96 HRAS PIK3CA
48 10.83 NFKBIA PIK3CA
49 10.79 HRAS NRAS
50 10.73 HOTAIR TP53

GO Terms for Nasopharyngeal Carcinoma

Biological processes related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras protein signal transduction GO:0007265 8.8 HRAS NRAS TP53

Sources for Nasopharyngeal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....